Tolerability and Immunogenicity Study of FLUVAL P H1N1 Monovalent Influenza Vaccine of Omninvest in Children and Adolescents.

Trial Profile

Tolerability and Immunogenicity Study of FLUVAL P H1N1 Monovalent Influenza Vaccine of Omninvest in Children and Adolescents.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 May 2012

At a glance

  • Drugs Influenza A virus vaccine-H1N1; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 01 Aug 2011 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top